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EXECUTIVE SUMMARY
Depression is highly prevalent among people living with HIV in Malawi, as in other countries 
across the globe. Depression can undermine ART adherence, retention in care, and, ultimately, 
viral suppression. Identifying and treating depression may be key to improving engagement in 
care across the HIV care continuum.
In Malawi, as in other sub-Saharan countries, mental health care infrastructure and resources 
are limited. Accordingly, there is a clear need to shift the provision of mental health treatment 
to the primary care level. The Malawi Ministry of Health, in partnership with UNC Project-Malawi, 
designed a program that would integrate depression screening and management into HIV care 
at two public HIV clinics in Lilongwe, Malawi. The purpose of this study, conducted under Project 
SOAR, was to evaluate the implementation of this program and its impact on HIV and mental 
health outcomes.
METHODOLOGY
The primary objective of this study was to evaluate the impact of a practical, evidence-based 
mental health treatment program integrated with HIV care, feasible for scale-up within the Malawi 
health system, on mental health and HIV treatment outcomes. The program focused on training 
existing ART staff and providers to screen for depression and prescribe antidepressants and 
training existing lay health workers as depression counselors. 
The study employed a pre-post multiple baseline design in two public health clinics in urban 
Lilongwe. All patients starting ART and identified as having mild, moderate, or severe depressive 
symptoms (PHQ-9 score ≥5) during the screening phase were followed forward until six months 
after ART initiation for HIV appointment attendance, viral load, and depressive symptom 
outcomes. During the screening (“pre“) phase, depression screening was integrated into ART 
initiation and providers were re-oriented to existing depression treatment options. During the 
active (“post“) phase, providers were additionally trained in algorithm-guided antidepressant 
prescription for moderate to severe depression, and lay health workers were trained in Friendship 
Bench problem-solving therapy for mild depression. 
Data were collected from clinical records on HIV appointment attendance, viral suppression, and 
depressive symptoms during the first six months after ART initiation. 
KEY FINDINGS
Feasibility of integrating depression screening 
Depression screening proved highly feasible to integrate with ART initiation. Screening was 
divided such that the initial 2-item PHQ-2 screen was completed with the HIV post-test counselor, 
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and only those with a positive PHQ-2 score went on to complete the full PHQ-9 with their HIV 
clinician. Overall, among 2,069 patients initiating ART during the study, 96 percent completed the 
full depression screening process; only 4 percent either did not complete the PHQ-2, or scored 
positive on the PHQ-2 and failed to complete the PHQ-9. 
Characteristics of patients
Patient characteristics were comparable between the screening and active phases, supporting 
the argument that the study design appropriately controlled for confounding. In both phases 
slightly fewer than half of patients were male; the mean age was approximately 33.8 years; 
virtually all patients were asymptomatic (WHO Stage I); approximately 25 percent of patients had 
mild, moderate, or severe depressive severity; and approximately 5 percent of patients indicated 
passive or active suicidal thoughts. 
Feasibility of initiating depression treatment
Depression treatment initiation also proved feasible to integrate into ART care. Of the 156 
patients identified with mild depression during the active phase, 87 percent initiated Friendship 
Bench counseling. Of the 55 patients identified with moderate to severe depression, 96 percent 
initiated an antidepressant. 
Consistency of HIV appointment attendance 
Loss to HIV care was high. Fully one-quarter of patients did not return for their first ART refill 
appointment, and over half were out of care at six months. These results were comparable during 
the screening and active phases. 
Feasibility of sustaining depression treatment 
Sustaining depression treatment proved challenging, in part because many patients missed 
follow-up ART appointments or were quickly lost to care. Of the 140 patients who started the 
Friendship Bench, 57 percent attended at least two sessions and 33 percent attended at least 
four sessions out of the recommended six sessions. Although the Friendship Bench was originally 
designed as a weekly program, most patients cited time or financial barriers to making extra trips 
to the clinic and aligned follow-up counseling sessions with their monthly ART appointments. Of 
the 55 patients who were initially prescribed an antidepressant, 31 percent received at least 
three months of antidepressant prescriptions, while the remainder received only one or two 
months of medication before discontinuing. 
Program impact on HIV and depression outcomes
Our primary outcome was HIV treatment success at six months, stringently defined as never 
more than two weeks late to a scheduled appointment in the first six months of care and a viral 
load <1,000 copies/mL at approximately six months post-ART initiation. There was no evidence 
of improved HIV treatment success in the active phase (18%) relative to the screening phase 
(25%). Similarly, no difference between the phases was evident in a range of secondary outcomes 
including being in care at six months, proportion of ART appointments attended within one week, 
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consistent ART supply through six months, viral suppression at six months, and PHQ-9 depressive 
symptom severity score at six months. 
CONCLUSION AND RECOMMENDATIONS
The SOAR-Malawi Mental Health Project demonstrated that it is feasible to integrate universal 
depression screening and evidence-based antidepressant management and problem-solving 
therapy counseling into routine care using existing staff in low-resource ART clinics in Malawi. 
Different challenges were raised by integration of antidepressants and counseling. After a 1-day 
training, clinicians were comfortable initiating antidepressants and did so systematically with very 
little increased time cost. However, because of challenging medical record systems, returning 
patients on antidepressants were inconsistently identified and often did not have their depressive 
symptom level re-assessed or receive a refill of their antidepressant. Occasional stockouts 
also affected medication supply. Counseling, on the other hand, was not affected by stockouts 
or medical record challenges. However, counseling was significantly more time-intensive, and 
integration into the workload of existing staff proved infeasible. Further, follow-up for counseling 
was poor, and few patients ended up receiving the recommended six sessions. 
A large proportion of patients missed HIV appointments or stopped coming altogether in both 
the screening and active phases. Among those who did remain in care, viral suppression 
and depression remission at six months were both very high. We saw no evidence of greater 
improvement in HIV care or mental health outcomes with the depression treatment program 
relative to the screening phase. This may have been because most depression at ART initiation 
was time-limited adjustment disorder, because even the basic one-time counseling provided 
during the screening phase was impactful, or because ART initiation and subsequent physical 
health improvement led to mental health improvement in both phases. 
Several key recommendations arise from the SOAR-Malawi Mental Health Project.
First, efforts to integrate depression screening and treatment within routine ART care in resource-
limited settings are definitely feasible, but will greatly benefit from the following:
•	A dedicated on-site champion with strong investment in program success either through 
financial support, strong institutional commitment, or other strategies.
•	 Integration with electronic medical record systems where feasible (many clinics in Malawi use 
the Baobab electronic system for ART records), which would ensure that screening is completed 
and returning patients on antidepressant treatment are identified and re-assessed.
•	Dedicated counseling personnel (other research has demonstrated that community members, 
who may be willing to commit for a small stipend, can be trained and supervised to effectively 
deliver problem-solving therapy).
•	 Identification of appropriate and sustainable incentives (monetary or non-monetary) that will 
ensure that clinicians participate in clinical supervision sessions to maintain and enhance 
these new skills.
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•	 Identification of appropriate and sustainable means of support to encourage patients to 
complete the recommended weekly counseling sessions.
Second, this program did not find evidence that HIV care or mental health outcomes improved 
during the treatment program relative to the screening phase. While this program focused on 
patients newly initiating ART as a population at high risk for loss to care, depression treatment 
may be more important for returning patients who may present with more persistent or severe 
depressive symptoms and face challenges in maintaining long-term ART adherence and HIV care 
engagement. Therefore, programs that seek to integrate mental health screening and treatment 
into HIV primary care should not restrict themselves to new patients but should evaluate the 
mental health needs of all patients.
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INTRODUCTION
Depression is highly prevalent among people living with HIV in Malawi as in other countries across 
the globe. While research in Africa is limited, studies have found that depression affects 18 to 
30 percent of people living with HIV (Nakimuli-Mpungu et al. 2011). In Malawi, the prevalence 
of depression among people living with HIV varies between 1 and 19 percent (Dow et al. 2014; 
Harrington et al. 2018; Kim et al. 2014; Malava et al. 2018). The high prevalence of depression 
among this vulnerable group indicates a need for mental health screening and treatment.
Depression can undermine ART adherence, retention in care, and, ultimately, viral suppression. 
Depression is a barrier to ART retention and is associated with reduced ART adherence and viral 
suppression (Franke et al. 2013; Gonzalez et al. 2011; Kidia et al. 2015; Nakimuli-Mpungu et al. 
2011; Pence et al. 2007; Smillie et al. 2014) as well as greater perceived stigma and faster HIV 
clinical progression (Gonzalez et al. 2011; Ickovics et al. 2001; Leserman et al. 2007; Leserman 
2008; Pence et al. 2007). Fortunately, some studies have shown that depression treatment may 
improve ART adherence and other HIV outcomes (Gaynes et al. 2015; Sin and DiMatteo 2014; 
Tsai et al. 2010; Walkup et al. 2008; Yun et al. 2005). Identifying and treating depression may be 
key to improving engagement in care across the HIV care continuum. 
In Malawi, as in other sub-Saharan African countries, there are significant barriers to mental 
health care seeking and limited mental health care infrastructure and resources. Stigma, cultural 
beliefs around mental illness, and lack of knowledge of mental health all negatively impact 
access to mental health care services (Crabb et al. 2012; Udedi 2016). The country currently 
treats mental healthcare as a specialized service, often only provided by mental health specialists 
in specialized tertiary facilities. Furthermore, there are few such specialists and facilities; there 
are only three psychiatrists and three functioning public psychiatric hospitals in the country 
(Udedi et al. 2018). As it is unlikely that the number of specialized service providers and 
infrastructure could grow rapidly enough to meet the demands of the population, there is a clear 
need to shift the provision of mental health treatment to the primary care level. 
Depression screening and management programs and tools for non-mental health specialists in 
Africa exist. Validated screening tools for depression, such as the Patient Health Questionnaire-9, 
are now available for the sub-Saharan region (Ali, Ryan, and De Silva 2016; Chorwe-Sungani and 
Chipps 2017). Depression treatment programs using antidepressant and psychosocial therapies 
have also been developed (Adams et al. 2012a; Adams et al. 2012b; Chibanda et al. 2011; 
Chibanda et al. 2016; Gaynes et al. 2015; Pence et al. 2014; Wagner, Slaughter, and Ghosh-
Dastidar 2017). Notably, in Cameroon, a measurement-based care program successfully treated 
depression among people living with HIV (Gaynes et al. 2015; Pence et al. 2014). In Zimbabwe, 
a problem-solving therapy intervention delivered by lay health workers proved efficacious 
in improving common mental disorders among patients in primary care in a large cluster-
randomized trial (Chibanda et al. 2017; Chibanda et al. 2011; Chibanda et al. 2016). While 
such programs have proven to be efficacious, they are infrequently adapted, implemented, and 
evaluated in real-world programmatic contexts in the sub-Saharan region. 
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The Malawi Ministry of Health (MOH) has committed to achieving the UNAIDS 90-90-90 goals, 
calling for 90 percent of those HIV-infected to be aware of their status, 90 percent of those 
aware of their status to be on sustained antiretroviral therapy (ART), and 90 percent of those on 
ART to be virally suppressed (UNAIDS 2014). Simultaneously, the noncommunicable diseases 
(NCDs) and Mental Health Unit of the Malawi MOH has prioritized the integration of mental health 
services into other general health services and the development of mental health capacity of 
general providers (Government of Malawi Ministry of Health 2013; Government of Malawi Ministry 
of Health 2017; Lupafya et al. 2016). The MOH, in partnership with UNC-Project Malawi, designed 
a program that would integrate depression screening and management into HIV care at two public 
HIV clinics in Lilongwe, Malawi. The purpose of this study, conducted under Project SOAR, was to 
evaluate the implementation of this program and its impact on HIV and mental health outcomes.
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METHODOLOGY
OBJECTIVES
The primary objective of this study was to evaluate the impact of a practical, evidence-based 
mental health treatment program integrated with HIV care, feasible for scale-up within the Malawi 
health system, on mental health and HIV treatment outcomes. Specifically, among all patients 
with mild, moderate, or severe depression, we aimed to evaluate the impact of the program on 
the following primary HIV outcomes:
 y Proportion of patients attending sufficient HIV appointments to maintain ART supply through the 
first six months on ART (i.e., all monthly appointments through six months).
 y Number of monthly HIV appointments attended in the first six months on ART.
 y Proportion of patients with a HIV RNA viral load of <1,000 copies/mL approximately six months 
after starting ART.
We further focused on the following secondary mental health outcomes:
 y Proportion of patients with remission of depressive symptoms, defined as a PHQ-9 score <5, at 
six months.
 y Proportion of patients with a decrease of 50 percent or more in depressive symptoms from 
baseline to six months.
STUDY DESIGN
This study employed a pre-post multiple baseline design to evaluate the impact of integrating 
the depression treatment program within existing HIV clinical services on HIV and mental health 
outcomes (Figure 1). Working in two public health clinics in urban Lilongwe, we launched a 
Screening phase in both clinics in April and May 2017. The screening phase lasted 7 months 
at Clinic A and 11 months at Clinic B. All patients starting ART and identified as having mild, 
moderate, or severe depressive symptoms (PHQ-9 score ≥5) during the screening phase were 
followed forward until six months after ART initiation for HIV appointment attendance, viral load, 
and depressive symptom outcomes, even if this follow-up extended into the second (active) 
phase.
At the conclusion of the screening phase, each clinic transitioned into the active phase. The 
active phase lasted 12 months at Clinic A and six months at Clinic B. All patients starting ART and 
identified as having mild, moderate, or severe depressive symptoms during the active phase were 
followed forward until six months after ART initiation for the same outcomes listed above. 
The screening and active phases are described in more detail in the next section. 
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DESCRIPTION OF INTERVENTION
We integrated a depression screening and treatment program in two phases at two public HIV 
clinics in Lilongwe, Malawi. 
The first phase, known as the “screening“ phase, of the program launched in April 2017. During 
this phase, we trained existing HIV post-test counselors and HIV providers to screen patients for 
depression using the Patient Health Questionnaire-2 (PHQ-2) and, for those screening positive, 
complete further assessment with the PHQ-9 to identify depressive symptom severity. ART 
providers also received a refresher training on the existing care options for depression, typically 
brief, single-session counseling by the ART provider, referral to off-site specialized psychiatric 
services, or (rarely) prescription of amitriptyline. Amitriptyline was commonly available at both 
clinics during the screening phase, as it is used to treat peripheral neuropathy, but providers had 
limited familiarity with its use as an antidepressant and were most comfortable prescribing it at 
doses for peripheral neuropathy that would be subtherapeutic for depression. Fluoxetine was not 
available during the screening phase.
We also trained providers in assessment of and response to suicidal thoughts as indicated by any 
response other than “Never“ on question 9 of the PHQ-9, which asks about any thoughts of being 
better off dead or considering hurting oneself in the past two weeks. For patients endorsing any 
such thoughts, providers were trained to complete a Suicide Risk Assessment form which guided 
them through evaluating whether such thoughts were passive (thoughts of being better off dead) 
or active (thoughts of actually hurting oneself), and the degree of severity of these thoughts or 
behaviors. Providers were trained in the appropriate response depending on the level of severity 
of the thoughts, ranging from brief safety assessment to immediate transport to the outpatient 
psychiatric department at a nearby hospital.
In the second phase, known as the “active“ phase, ART providers were trained to provide 
algorithm-based care for depression (ABCD). ABCD directs providers to refer patients with mild 
depression for a problem-solving therapy intervention, while patients with moderate to severe 
depression are initiated on antidepressants using an algorithm known as Measurement Based 
Care (MBC). The problem-solving therapy intervention received by patients with mild depression 
Figure 1  Study design
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was the evidence-based psychosocial counseling strategy originally developed in Zimbabwe 
(The Friendship Bench) (Chibanda et al. 2011). The Friendship Bench tailored for the Malawi 
setting was intended to be six 30- to 45-minute sessions over six weeks and was delivered by 
clinic-based lay health workers, known as Health Surveillance Assistants (HSAs). There was no 
expectation that patients would necessarily see the same counselor from one session to the next, 
although patients and counselors could try to arrange for continuity if possible; staff availability 
was the primary driver of which counselor was seen at the patient’s next return visit. 
MBC directs providers to prescribe antidepressants (either fluoxetine or amitriptyline) and titrate 
the dose accordingly based on antidepressant side effects and depression symptom severity 
(PHQ-9 score) to patients with moderate to severe depression. ART providers re-administer the 
PHQ-9 to patients at their monthly ART visits to monitor their depressive symptoms and manage 
their treatment accordingly.
DATA COLLECTION METHODS
During both the screening and active phases, research assistants approached patients newly 
initiating ART and invited them to participate in the program evaluation. Consenting patients 
allowed the abstraction of their clinical data. To evaluate the impact of the program on HIV and 
mental health outcomes, we abstracted mental health and HIV data from consenting patients’ 
clinical records from ART initiation up to a total of 13 months in care. Data included HIV 
appointment attendance, ART medication dispensed, HIV viral load results, depression treatment 
information (counseling sessions and antidepressants prescribed), and follow-up depressive 
symptom assessments. 
Patients with depressive symptoms received care according to the current phase (screening or 
active) regardless of whether or not they provided consent for their data to be abstracted. 
Box 1  Screening phase vs active phase explained
Screening phase Active Phase
Depression screening Integrated into HTC (PHQ-2 administered by counselors) and ART 
initiation (PHQ-9 completed by ART clinicians or nurses)
Depression treatment Standard care Algorithm-based care for 
depression
No or minimal depression None None
Mild depression Potential to include additional 
counseling during ART, amitriptyline 
prescription (typically at sub-
therapeutic dose), or referral to 
mental health specialists
Friendship Bench counseling 
provided by trained HSAs
Moderate to severe
depression
Measurement Based Care 
prescription of antidepressants 
(amitriptyline or fluoxetine) by 
ART clinicians or nurses
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ETHICAL REVIEW
The protocol was approved by the National Health Sciences Research Committee of Malawi 
(NHSRC) and the Biomedical Institutional Review Board (IRB) of the University of North Carolina 
at Chapel Hill. All research activities adhered to Malawian and US ethical standards for research 
in human subjects. To ensure protection of patients’ identities and confidentiality, the study only 
used routinely collected, de-identified clinical data to evaluate this treatment program. 
DATA ANALYSIS 
We begin by comparing the characteristics of those enrolled in the screening vs. active phases 
to evaluate comparability of the two populations. We continue with descriptive information 
about depression screening, treatment initiation, and treatment continuation, as well as on HIV 
appointment attendance over the first six months on ART. We then compare the primary and 
secondary outcomes between the screening and active phases. 
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KEY FINDINGS
FEASIBILITY OF DEPRESSION SCREENING INTEGRATION
Between April 2017 and November 2018, 2,414 patients newly initiated ART at the two study 
sites. Approximately 86 percent (n=2,067) of patients who newly initiated ART during this period 
consented to allow the abstraction of their clinical data to evaluate the program. Nearly all 
of consenting individuals (n=2,063) were screened with the PHQ-2, and 96 percent of those 
screened with the PHQ-2 successfully completed depression screening. A quarter of the new ART 
initiators reported mild (19%), moderate (6%), or severe (<1%) depressive symptoms (Figure 2).
Figure 2  Evaluation enrollment
CHARACTERISTICS OF CONSENTING PARTICIPANTS
We enrolled 2,067 individuals in our program evaluation; 1,131 initiated during the screening 
phase and 936 initiated during the active phase (Table 2). Just under half of participants were 
male (47%). The mean age of participants (33.8) did not vary appreciably between the screening 
and active phases. According to the World Health Organization’s (WHO) HIV clinical stages for 
HIV surveillance (WHO 2005), nearly everyone (N=2,064) was classified as asymptomatic (Stage 
1). Overall, 43 percent of participants scored above 0 on the PHQ-2, 19 percent reported mild 
depression (PHQ-9 score 5–9), and 7 percent reported moderate to severe depression (PHQ-9 
Missed: 4
Consented: 2,067 (86%)
Screened with PHQ-2: 2,063 (>99%)
Missed: 79
New ART patients: 2,414
Screened with PHQ-9: 1,984 (96%)
PHQ-9 score 0–4:  
1,483 (75%)
PHQ-9 score 5–9:  
370 (19%)
PHQ-9 score 10–19: 
1,483 (75%)
PHQ-9 score 20–27:  
5 (<1%)
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score ≥10). The prevalence of suicidality was approximately 5 percent, with most being passive 
suicidal ideation. There were no notable differences by sex.
Table 2  Characteristics of consenting patients
Overall
n (%) or mean (sd)
Screening phase
n (%) or mean (sd)
Active phase
n (%) or mean (sd)
Overall 2,067 1,131 936
Clinic
Clinic A 1,143 (55%) 460 (41%) 683 (73%)
Clinic B 924 (45%) 671 (59%) 253 (27%)
Sex
Male 980 (47%) 530 (47%) 450 (48%)
Female 1,087 (53%) 601 (53%) 486 (52%)
Age 33.8 (9.3) 33.5 (9.6) 34.2 (8.9)
WHO stage
I 2,062 (100%) 1,129 (100%) 933 (100%)
II–IV 5 (0%) 2 (0%) 3 (0%)
Depressive symptom severity
Screen-negative (PHQ-2 score = 0) 1,134 (57%) 602 (55%) 532 (60%)
Minimal symptoms (PHQ-9 score 1–4) 349 (18%) 199 (18%) 150 (17%)
Mild symptoms (PHQ-9 score 5–9) 370 (19%) 214 (20%) 156 (17%)
Moderate symptoms (PHQ-9 score 10–19) 126 (6%) 71 (6%) 55 (6%)
Severe symptoms (PHQ-9 score 20–27) 5 (0%) 5 (0%) 0 (0%)
Not assessed 83 40 43
Suicidal thoughts
No thoughts 1,876 (95%) 1,026 (94%) 850 (95%)
Passive thoughts 56 (3%) 35 (3%) 21 (2%)
Active thoughts 46 (2%) 27 (2%) 19 (2%)
Not assessed 6 (0%) 3 (0%) 3 (0%)
FEASIBILITY OF INITIATING DEPRESSION TREATMENT 
During the screening phase, the majority of patients both with mild and moderate to severe 
depression received brief counseling from their HIV clinician. During the active phase, 86 percent 
of participants with mild depressive symptoms started Friendship Bench counseling and 96 
percent of participant with moderate to severe depressive symptoms started an antidepressant 
(Table 3). Treatment initiation indicators were comparable between the two clinics in the active 
phase.
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Mild depressive symptoms (PHQ-9 score 5–9)* 214 (100%) 156 (100%)
Counseling by HIV clinician 191 (89%) 15 (10%)
Counseling by Friendship Bench (FB) counselor 0 (0%) 134 (86%)
Antidepressant (AD) 1 (0%) 0 (0%)
AD & clinician counseling 1 (0%) 0 (0%)
AD & FB counseling 0 (0%) 2 (1%)
None* 21 (10%) 5 (3%)
Moderate to severe depressive symptoms (PHQ-9 score ≥10) 76 (100%) 55 (100%)
Counseling by HIV clinician 60 (79%) 2 (4%)
Counseling by FB counselor 0 (0%) 0 (0%)
AD 7 (9%) 41 (75%)
AD & clinician counseling 7 (9%) 8 (15%)
AD & FB counseling 0 (0%) 4 (7%)
None 2 (3%) 0 (0%)
*Those with missing baseline treatment plan (n=4) treated as none; AD=antidepressants, FB=Friendship Bench
CONSISTENCY OF HIV APPOINTMENT ATTENDANCE 
After ART initiation, about three quarters of participants in both phases returned for their 1-month 
ART appointment whereas about one-quarter did not (28% and 25% during the screening and 
active phase, respectively) (Figures 3 & 4). Attendance continued to decline thereafter. By the 
6-month appointment window, only 36 percent and 35 percent attended an appointment during 
the screening and active phase, respectively; another 10 percent (screening phase) and 6 
percent (active phase) had been given a 60- or 90-day supply of ART at an earlier appointment 
and were not expected to attend at six months. A small number of patients were known to have 
died or transferred care, but a much larger proportion missed an appointment or were lost to 
care (defined as having gone at least 30 days without ART, i.e., the prior scheduled appointment 
was missed and the patient had gone at least 30 more days beyond the expected date of running 
out of ART without an attended appointment). These follow-up rates are fairly comparable to 
the clinic’s overall retention rate, with about 44 percent of all patients during this period either 
attending an appointment or having an extended supply of ART (prior 60- or 90-day dispensed 
supply) at six months. There were no notable differences by sex. 
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Figure 3  Screening phase: HIV appointment attendance during first 6 months on ART 
*Month 1=Days 1-45; Month 2=Days 46-76; Month 3=Days 77-106; Month 4=107-137; Month 5=138-167; Month 6=Days 
168-197
**Patient has gone at least 30 days without ART, i.e., the prior scheduled appointment was missed and the patient had gone at 
least 30 more days beyond the expected date of running out of ART without an attended appointment
 
Figure 4  Active phase: HIV appointment attendance during first 6 months on ART 
*Month 1=Days 1-45; Month 2=Days 46-76; Month 3=Days 77-106; Month 4=107-137; Month 5=138-167; Month 6=Days 
168-197
**Patient has gone at least 30 days without ART, i.e., the prior scheduled appointment was missed and the patient had gone at 
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FEASIBILITY OF SUSTAINING DEPRESSION TREATMENT
An adequate course of depression treatment consists of six Friendship Bench counseling 
sessions or at least three months of continuous antidepressant prescription with dosage 
adjustments if indicated. Few patients received an adequate course of treatment, in part due 
to the low overall HIV care retention rate and in part due to patients who attended clinic not 
receiving follow-up depression care; the majority of inadequate depression treatment was due to 
patients not returning to clinic, but a large proportion was also due to returning patients not being 
identified for follow-up care (Appendix figures 5 and 6). During the active phase, only around one-
third of individuals who were directed to receive Friendship Bench counseling completed four 
or more sessions in their first six months of care (Table 4). In addition, only 18 percent (n=10) 
of participants who were prescribed antidepressants at ART initiation received antidepressants 
at four or more sessions over their first six months of care. Of these five individuals, only two 
received four consecutive months of antidepressant prescriptions. 




Clinic A Clinic B
Of those directed to FB counseling* 140 (100%) 107 (100%) 33 (100%)
Number of FB sessions attended
1 60 (43%) 31 (29%) 29 (88%)
2 21 (15%) 19 (18%) 2 (6%)
3 13 (9%) 12 (11%) 1 (3%)
≥4 46 (33%) 45 (42%) 1 (3%)
Of those prescribed AD** 55 (100%) 44 (100%) 11 (100%)
Number of months of AD provided
1 23 (42%) 14 (32%) 9 (82%)
2 15 (27%) 13 (30%) 2 (18%)
3 7 (13%) 7 (16%) 0 (0%)
≥4 10 (18%) 10 (23%) 0 (0%)
FB=Friendship Bench; AD=Antidepressants
PROGRAM IMPACT ON HIV AND DEPRESSION OUTCOMES
The primary outcome of this evaluation was HIV clinical success. HIV clinical success was 
defined as meeting both of the following criteria: never more than two weeks late to a scheduled 
appointment in the first six months of care and a viral load <1,000 copies/mL at the viral load 
assessment conducted at approximately six months post-ART initiation. Overall, only one-quarter 
of patients achieved HIV clinical success; 28 percent of patients from the screening phase and 
22 percent of patients in the active phase (Table 5). There were no notable differences by sex. 
Approximately one-third of patients from both the screening and active phases were retained 
through six months (never more than two weeks late to a scheduled appointment in the first six 
months). Nearly every patient with a measured viral load demonstrated viral suppression at six 
months (94% and 91% in screening and active phase, respectively). Similarly, nearly every patient 
with a 6-month PHQ-9 score achieved depression remission (94% and 97% in the screening and 
active phases, respectively). The HIV and depression outcomes did not vary appreciably between 
phases. 
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Table 5  Program impact on HIV and depression outcomes among patients with mild, moderate, 













HIV clinical success: Never >14 days late to an appointment 
through 6 months and virally suppressed at 6 months
Yes 102 (25%) 68 (28%) 34 (22%)
No 301 (75%) 178 (72%) 123 (78%)
Retained, but missing viral load 49 20 29
Transferred out 49 24 25
SECONDARY OUTCOMES
Retained through 6 months: Never >14 days late to an 
appointment
Yes 157 (35%) 91 (34%) 66 (35%)
No 295 (67%) 175 (66%) 120 (65%)
Transferred out 49 24 25
Currently on ART: Attended an appointment prior to 6 months with 
a next appointment date after 6 months
Yes 225 (50%) 138 (52%) 87 (46%)
No 227 (50%) 128 (48%) 99 (54%)
Transferred 49 24 25
Proportion of scheduled HIV appointments attended within 1 week 
[Mean (SD)] 0.57 (0.39) 0.57 (0.39) 0.59 (0.38)
Consistent ART supply through 6 months: Never >5 days without 
ART
Yes 185 (41%) 112 (42%) 73 (39%)
No 267 (59%) 154 (58%) 113 (61%)
Transferred out 49 24 25
ART pill possession ratio* [Mean (SD)] 0.68 (0.36) 0.69 (0.35) 0.67 (0.37)
Virally suppressed at 6 months**
Yes 168 (93%) 108 (94%) 60 (91%)
No 13 (7%) 7 (6%) 6 (9%)
Retained, but no VL drawn 74 39 35
No attended appointment between months 5.5 and 8 197 112 85
Transferred out 49 24 25
Depression remission (PHQ-9 score <5) at 6 months
Yes 124 (95%) 87 (94%) 37 (97%)
No 7 (5%) 6 (6%) 1 (3%)
Attended appointment but no PHQ-9 completed 110 51 59
No attended appointment between months 5.5 and 8 211 122 89
Transferred out 49 24 25
PHQ-9 score at 6 months** [Mean (SD)] 1.0 (2.4) 1.2 (2.7) 0.6 (1.4)
VL=Viral Load; SD=Standard Deviation
*Proportion of 6 months (183 days) with ART. Numerator is the cumulative number of pills dispensed through 6 months. Pills 
dispensed at last visit before 6-month prorated to be equivalent to the number of days between that visit and day 183 in care. 
** Take from the first viral load/PHQ-9 after at least 5.5 months in care 
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DISCUSSION 
The objective of this study was to integrate a practical, feasible depression treatment program 
into routine, real-world HIV care in Malawi and evaluate the impact of that integration on HIV and 
mental health outcomes for patients newly initiating ART. The program was highly successful in 
effectively integrating depression screening, assessment, and treatment initiation using existing 
staff, but faced greater challenges in ensuring continuity of depression care at follow-up visits. 
Generally, loss to HIV care was very high both before and after the program implementation, 
but those patients retained in HIV care almost universally demonstrated viral suppression and 
depression remission. There was no evidence of greater improvement in HIV or mental health 
outcomes under the integrated program compared to the pre-implementation screening phase. 
We were able to successfully integrate depression screening and treatment initiation into 
starting HIV care. Over the course of this program, nearly all new ART initiators were screened for 
depression with the PHQ-2, and 92 percent of patients with positive PHQ-2 screens completed the 
PHQ-9. About one-quarter of study participants had mild to severe depression at ART initiation. 
While a high percentage of participants started the appropriate depression treatment during the 
active phase, few patients continued to receive counseling or antidepressants over their first six 
months of care. 
We attribute the success in integration of depression screening and treatment initiation to several 
factors. First, we found that effectively utilizing existing ART initiation processes and infrastructure 
was key (Udedi et al. 2018). For example, after careful study of the clinic flow, the additional work 
and time burden of screening patients and initiating treatment was split across the HIV post-test 
counselors and HIV providers. Additionally, we invested heavily in creating multiple opportunities 
for iterative and collaborative learning (Udedi et al. 2018). We ensured that every HIV provider 
received training in how to administer and interpret the PHQ-9, provide depression treatment, and 
manage depressive symptoms over time. 
However, sustaining depression management was challenging for the health care facilities. This 
was in part due to structural challenges. At these clinics, providers typically use an electronic 
medical record (EMR) system to manage ART care, with a parallel paper system populated with 
barcodes from the EMR. As resources were lacking to build a depression module into the ART 
EMR, we modified the paper recordkeeping system to track both ART and depression indicators. 
Nevertheless, providers struggled to re-identify depressed patients returning for care so as to 
provide appropriate follow-up. While the program team and the clinic staff worked together to 
engineer a solution for this challenge by marking patients’ health passports, ultimately it was 
difficult to overcome. 
Furthermore, antidepressant stock-outs were common. Ostensibly, Malawi’s Essential Health 
Package guarantees the availability of fluoxetine and amitriptyline free of charge for patients at 
public clinics in Malawi (Government of Malawi Ministry of Health 2013). However, in practice 
ensuring their availability at the clinic proved complicated, requiring substantial coordination 
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between the providers, the clinic pharmacies, the clinic leadership, the district health officer, the 
district health office pharmacy, and the national level medication reserves, often facilitated by 
project staff. Other countries in the region such as Mozambique also have an essential drug list 
that includes amitriptyline and fluoxetine; however, a recent study found that these drugs were 
not frequently available at the district or clinic level (Wagenaar et al. 2015). 
The clinics also faced some difficulties ensuring provision of Friendship Bench counseling with 
existing staff. While the study did hire one dedicated Friendship Bench counselor at each clinic, 
these study counselors were meant to provide back-up for the larger group of MOH-employed 
community health workers trained as counselors. However, the study-employed counselors 
ultimately provided the majority of the counseling at both sites, as the community health workers 
had a very high workload and often traveled off-site to run various Ministry of Health initiatives. 
Furthermore, while the original Friendship Bench protocol called for six weeks of weekly 
Friendship Bench counseling sessions, nearly all patients were unable or unwilling to make extra 
trips to the clinic for counseling sessions without compensation due to time and transportation 
costs. As a result, nearly all of the Friendship Bench counseling sessions were provided monthly, 
on the same day at the ART appointment, which may have impacted the effectiveness of the 
counseling protocol. Future efforts to implement counseling protocols such as the Friendship 
Bench should consider carefully (1) the capacity of the cadre designated to provide the 
counseling and (2) how to support patients in regular attendance at sessions, for example with 
transportation assistance or possibly community-based delivery of counseling. 
This population proved a very challenging group to keep engaged in treatment. We observed 
very high rates of loss to HIV care at both clinics, with only about one-quarter of participants 
remaining consistently in care for the first six months and having a suppressed viral load. Even 
when considering a somewhat more lenient definition of having ART at six months, fully half 
of patients did not meet this definition. However, of those attending appointments and with 
viral loads drawn around six months, nearly all were virally suppressed in both phases. These 
and several other secondary measures of HIV care engagement showed no notable difference 
between the screening and active phases. There are several possible explanations for this result. 
First, those patients identified with depressive symptoms at ART initiation may have had a time-
limited reactive depression or adjustment disorder rather than major depressive disorder, which 
may have resolved independently of treatment in both phases. Indeed, depression remission 
was extremely high among those who stayed in care and had a completed PHQ-9 around six 
months—both among those with mild and those with moderate to severe depression at baseline. 
Second, for patients with no prior exposure to any sort of mental health care, even the very basic 
clinician-delivered counseling provided during the screening phase may have led to depression 
improvements, reducing the difference between the two arms. Ethically, it was not possible to 
have a pure “usual care“ phase where patients were screened and identified with depression 
but no information was provided to clinicians and no clinical follow-up was permitted. Third, 
depressive symptoms may have improved for all patients with the initiation of antiretroviral 
therapy and the subsequent improvement in physical health. Indeed, several studies have found 
such improvements among ART initiators in Africa (Okeke and Wagner 2013, Wagner et al. 2012). 
This improvement may have masked the added benefit of the depression treatment program 
in this population. Finally, although uptake of depression screening and depression treatment 
initiation were high, achieving sustained depression treatment for multiple months proved 
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challenging in this real-world context, which may also have limited the difference between the 
screening and active phases. 
LIMITATIONS
Our results should be carefully considered in light of several limitations. First, since the 
primary outcome of the study was retention in HIV care, the study team intentionally did not 
schedule research follow-up interviews, especially for the 6-month outcome, that could have 
had the unintended effect of bringing participants back to clinic during the first six months and 
influencing the primary outcome. Therefore. the extent of participants without 6-month viral 
load and depression measures was greater than it would have been had the research team 
scheduled follow-ups with participants. If those who did not remain in care were more likely to 
have persistent depressive symptoms, the rate of depression remission reported here would be 
an overestimate. Further, PHQ-9s at 6-month follow-up were administered by clinicians as part of 
routine care. It is possible that part of the reduction in PHQ-9 scores observed between baseline 
and six months reflected less careful administration by clinicians at the later time point. 
The primary objective of the study was to estimate the impact of the depression treatment 
program on HIV outcomes among the full patient population at the clinic. Since the primary 
outcome could be assessed purely relying on medical chart data, the team decided not to include 
a baseline patient interview that would have limited enrollment to those willing to spend the 
additional time for the interview. As a result, very limited information is available on potential 
confounders. However, the multiple baseline design should have protected against confounding 
by producing balanced characteristics of patients in the screening and active phases; indeed, all 
measured characteristics were very similar between the two phases. 
Causal inference from this study relies on the validity of the multiple baseline design and 
specifically the comparability of the patient population at each clinic during the screening and 
active phases (or lack of confounding). As noted above, lack of confounding is supported by the 
comparable distributions of measured characteristics between the screening and active phases. 
Although the primary outcome used for this study (attending sufficient HIV appointments to 
maintain ART supply through six months and having a suppressed viral load at six months) is 
more stringent than the standard PEPFAR definition of retention in care, we saw similar results 
with several different definitions of HIV care engagement, including the standard PEPFAR 
measure (Table 5). 
Finally, the primary outcome of retention in HIV care may have been influenced by “silent 
transfers,“ or patients who switched care to another ART clinic without formally transferring their 
records. Patients who requested record transfers were recorded as transfers, but any patients 
who transferred silently would have been potentially misclassified as being out of care. However, 
there is no reason to believe that the rate of silent transfers would have varied between the 
screening and active phases, and therefore this potential measurement error should not have 
introduced bias into the primary analyses. 




The SOAR-Malawi Mental Health Project demonstrated that it is feasible to integrate universal 
depression screening and evidence-based antidepressant management and problem-solving 
therapy counseling into routine care using existing staff in low-resource ART clinics in Malawi. 
Although there was some initial resistance from clinicians to added work with no added pay, with 
persistence and involvement of clinic leadership the program was successful in achieving over 90 
percent coverage of depression screening and over 90 percent initiation of depression treatment 
among those identified with elevated depressive symptoms over an 18-month period. 
Although clinicians and staff received no extra pay or incentives, this success was not resource-
free. Beyond the one-time costs for training, success hinged on significant legwork and 
“championing“ by the study coordinator. Further, the training of existing Health Surveillance 
Assistants (clinic-based lay health workers) as problem-solving therapy counselors was not 
effective. Despite multiple efforts to organize rosters and ensure a shared workload, the existing 
HSAs were routinely pulled into other duties and not available for counseling. As a result, the 
study-funded counselor at each clinic did the vast majority of counseling sessions. 
Different challenges were raised by integration of antidepressants and counseling. After a one-
day training, clinicians were comfortable initiating antidepressants and did so systematically with 
very little increased time cost. However, because of challenging medical record systems, returning 
patients on antidepressants were inconsistently identified and often did not have their depressive 
symptom level re-assessed or receive a refill of their antidepressant. Further, although both 
amitriptyline and fluoxetine are on the government essential medications list, stockouts did occur, 
leading to medications being either discontinued or switched to the available antidepressant 
for some patients. In addition, although regular supervision is a critical aspect of supporting 
non-specialists in delivering depression care, very few clinicians attended the biweekly clinical 
supervisions held by the study team (for which no allowance was offered), even after multiple 
interventions with clinic and district leadership. 
Counseling, on the other hand, was not affected by stockouts or medical record challenges since 
patients knew where to find the counselor. However, counseling was significantly more time-
intensive, and integration into the workload of existing staff proved infeasible. Further, follow-up 
for counseling was poor. Patients, facing time and transportation costs, proved unable or unwilling 
to come to more frequent counseling sessions without travel reimbursement. As a result, 
counseling sessions occurred monthly at ART appointments rather than weekly as recommended, 
and few patients ended up receiving the recommended six sessions. 
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Retention in HIV care through the first six months on ART was poor at our two clinics in both 
the screening and active phases. Among those who did remain in care, viral suppression and 
depression remission at six months were both very high. We saw no evidence of improved 
HIV care or mental health outcomes with the depression treatment program relative to the 
screening phase. This may have been because most depression at ART initiation was time-limited 
adjustment disorder, because even the basic one-time counseling provided during the screening 
phase was impactful, or because ART initiation and subsequent physical health improvement led 
to mental health improvement in both phases. 
RECOMMENDATIONS
Several key recommendations arise from the SOAR-Malawi Mental Health Project.
First, efforts to integrate depression screening and treatment within routine ART care in resource-
limited settings are definitely feasible, but will greatly benefit from the following:
 y A dedicated, funded on-site champion.
 y Integration with electronic medical record systems where feasible (many clinics in Malawi use 
the Baobab Health electronic system for ART records), which would ensure that screening is 
completed and returning patients on antidepressant treatment are identified and re-assessed.
 y Dedicated counseling personnel (other research has demonstrated that community members, 
who may be willing to commit for a small stipend, can be trained and supervised to effectively 
deliver problem-solving therapy).
 y Identification of appropriate and sustainable incentives (monetary or non-monetary) that will 
ensure that clinicians participate in clinical supervision sessions to maintain and enhance 
these new skills.
 y Identification of appropriate and sustainable means of support to encourage patients to 
complete the recommended weekly counseling sessions.
Second, this program did not find evidence that HIV care or mental health outcomes improved 
during the treatment program relative to the screening phase. While this program focused on 
patients newly initiating ART as a population at high risk for loss to care, depression treatment 
may be more important for returning patients who may present with more persistent or severe 
depressive symptoms and face challenges in maintaining long-term ART adherence and HIV care 
engagement. 
Third, efforts to integrate depression care into HIV clinical services may need to consider the 
evolving ART delivery landscape, with increasing emphasis on reducing clinical appointments by 
providing multiple months’ ART supply and expanding community ART delivery. Integration efforts 
may need to be creative about where and when to engage patients in depression screening and 
care, and potentially consider different follow-up schedules for patients on stable ART without 
complications vs. patients who require more frequent follow-up for management of comorbidities 
such as mental health. 
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APPENDICES
PHQ-9 SCREENING
The Patient Health Questionnaire-9 (PHQ-9) is a widely used nine item instrument that assesses 
the presence of nine symptoms of depression within the previous two weeks as specified by 
the Diagnostic and Statistical Manual of Mental Disorders IV (American Psychiatric Association 
2000). Each of the nine items is scored from 0 (not at all) to 3 (nearly every day). The first two 
questions—known as the Patient Health Questionnaire-2 (PHQ-2)—capture depressed mood and 
anhedonia, the two core symptoms of depression. A total score of 5–9, 10–14, 15–19, or 20 
and above are considered indicative of mild, moderate, moderately severe, or severe depression, 
respectively (Kroenke, Spitzer and Williams 2001). 
The HIV testing and counseling (HTC) providers screened patients with the PHQ-2 after a positive 
test for HIV. ART providers then screened patients who scored above 0 on the PHQ-2 with the 
remaining seven questions of the PHQ-9, assessing for the presence of the remaining seven 
symptoms of depression. ART providers then used the PHQ-9 to reassess patients for depression 
at their subsequent ART follow-up visits.
The PHQ-9 is one of a number of mental health screening tools that have been used in Malawi 
and other African countries. It was chosen because it focuses specifically on depression, has 
been widely used and validated in many different settings (Gelaye et al. 2013), and works well 
both as a screening tool for depression as well as a longitudinal measure to monitor response 
to treatment. This tool had been validated for use in HIV-positive populations in other countries 
in the region (Cholera et al. 2014, Monahan et al. 2009) and had been used in one other study 
in Malawi (Malava et al. 2018). It has since been validated among a population of people 
living with diabetes. The standard PHQ-9 was augmented with an additional screening protocol 
to probe the degree of severity of suicidality in patients who screened positive for suicidal 
ideation on the PHQ-9. Both the PHQ-9 and associated suicide risk assessment protocol were 
translated into Chichewa, the vernacular language in the central region of Malawi. This entailed 
an iterative process involving the health workers to ensure that the PHQ-9 adequately captures 
the depressive symptoms yet is culturally understandable. The translated instrument is currently 
being validated. 





1. During the past two weeks, how many days have 








13 or 14 days
(3)
2. During the past two weeks, how many days have 













3. During the past two weeks, how many days have 
you been bothered by trouble falling or staying asleep, 







13 or 14 days
(3)
4. During the past two weeks, how many days have 








13 or 14 days
(3)
5. During the past two weeks, how many days have 







13 or 14 days
(3)
6. During the past two weeks, how many days have 
you been bothered by feeling bad about yourself—or 








13 or 14 days
(3)
7. During the past two weeks, how many days have 
you been bothered by trouble concentrating on things, 
such as reading, talking with friends, finishing tasks, 







13 or 14 days
(3)
8. During the past two weeks, how many days 
have you been bothered by moving or speaking so 
slowly that other people could have noticed? Or the 
opposite—being so fidgety or restless that you have 







13 or 14 days
(3)
9. During the past two weeks, how many days have 
you been bothered by thoughts that you would be 







13 or 14 days
(3)
FRIENDSHIP BENCH
The Friendship Bench therapy is an adapted form of problem-solving therapy that was developed 
over many years of formative research in Zimbabwe (Abas et al. 2016, Chibanda et al. 2011, 
Chibanda et al. 2016, Pierce 2012). Friendship Bench therapy consists of patient-centered 
counseling that teaches patients how to identify triggers and effectively manage stressful life 
events by learning or reactivating problem-solving skills. Specifically, counselors guide patients 
through recognizing problems, identifying their own solutions, implementing those solutions, 
and assessing the outcome (Chibanda et al. 2011, Pierce 2012). The original Friendship Bench 
was designed to be delivered by lay health care workers and called for patients to receive six 
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weekly counseling sessions. However, in line with the patient-centered approach, patients were 
encouraged to set their own return dates. 
During the active intervention phase of the program, ART providers were trained to refer 
participants with mild depressive symptoms (PHQ-9 score 5–9) to clinic-based lay health workers, 
called HSAs, or a project-employed counselor trained to provide Friendship Bench Therapy. The 
first session would often last about 45 minutes to an hour and subsequent sessions would 
be shorter (around 15 to 30 minutes). Patients referred to the Friendship Bench would ideally 
receive at least six counseling sessions over their first six months in care. Again, patients were 
encouraged to return weekly for Friendship Bench therapy, but ultimately patients set their own 
appointments in line with the protocol’s patient-centered approach. The program built covered 
shelters with seating areas at both clinics to serve as the Friendship Bench in an effort ensure 
there would be a dedicated space for the Friendship Bench counselors to work. 
MEASUREMENT BASED CARE
Measurement Based Care (MBC) is a resource-efficient, task-sharing model for prescribing 
antidepressant management in non-psychiatric settings. This model of care has demonstrated 
safety, feasibility, and acceptability when adapted for HIV care and delivered by general practice 
medical providers in Cameroon, Tanzania, and Uganda (Adams et al. 2012a, Pence et al. 2014, 
Wagner et al. 2016). The model of care uses PHQ-9 scores to monitor depressive symptoms 
in combination with an assessment of side effects and antidepressant tolerability to guide 
antidepressant prescription. 
During the active intervention phase, ART providers prescribed antidepressants to patients with 
moderate to severe depression (PHQ-9 ≥ 10). At the subsequent follow-up visits, ART providers 
would reassess patients’ depressive symptoms with the PHQ-9 and assess the medication’s 
tolerability. Providers would use changes in depressive symptoms and medication tolerability to 
guide management of patients’ antidepressant prescription, with options to increase or decrease 
the dose or change the type of antidepressant prescribed.






















Overall 2,414 2,216 (92%) 952 (43%) 862 (91%) 502 (58%) 502 (24%)
Clinic A 1,370 1,259 (92%) 557 (44%) 487 (87%) 276 (57%) 276 (23%)
Clinic B 1,044 957 (92%) 395 (41%) 375 (95%) 226 (60%) 226 (24%)
Screening phase 1,308 1,182 (90%) 533 (45%) 488 (92%) 287 (59%) 287 (25%)
Active phase 11,06 1,034 (93%) 419 (41%) 374 (89%) 215 (57%) 215 (22%)
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Study population, by clinic and period
Overall




n (%) or  
mean (sd)
Active phase 
n (%) or 
mean (sd)
Screening phase Active phase
Clinic A
n (%) or 
mean (sd)
Clinic B 
n (%) or 
mean (sd)
Clinic A 
n (%) or 
mean (sd)
Clinic B 
n (%) or 
mean (sd)
Overall [N] 2,067 1131 936 460 671 683 253
Clinic
Clinic A 1,143 (55%) 460 (41%) 683 (73%) 460 (100%) — 683 (100%) —
Clinic B 924 (45%) 671 (59%) 253 (27%) — 671 (100%) — 253 (38%)
Phase
Screening — — — 460 (100%) 671 (100%) — —
Active — — — — — 683 (100%) 253 (38%)
Sex
Male 980 (47%) 530 (47%) 450 (48%) 228 (50%) 302 (45%) 340 (50%) 110 (43%)
Female 1,087 (53%) 601 (53%) 486 (52%) 232 (50%) 369 (55%) 343 (50%) 143 (57%)
Age 33.8 (9.3) 33.5 (9.6) 34.2 (8.9) 33.9 (9.5) 33.1 (9.7) 34.7 (9.0) 32.9 (8.5)
WHO disease stage
I 2,062 (100%) 1,129 (100%) 933 (100%) 458 (100%) 671 (100%) 680 (100%) 253 (100%)




(PHQ-2 score = 0) 1,134 (55%) 602 (53%) 532 (57%) 237 (52%) 365 (54%) 361 (53%) 171 (68%)
Minimal symptoms 
(PHQ-9 score 1–4) 349 (17%) 199 (17%) 150 (16%) 82 (18%) 118 (18%) 120 (18%) 30 (12%)
Mild symptoms  
(PHQ-9 score 5–9) 370 (18%) 214 (17%) 156 (17%) 87 (19%) 128 (19%) 117 (17%) 39 (15%)
Moderate symptoms 
(PHQ-9 score 10–19) 126 (6%) 71 (6%) 55 (6%) 28 (6%) 43 (6%) 43 (6%) 12 (5%)
Severe symptoms  
(PHQ-9 score 20–27) 5 (0%) 5 (0%) 0 (0%) 1 (0%) 4 (1%)  (0%)  (0%)
Not assessed 83 40 43 25 15 42 1
Suicidal thoughts
No thoughts 1,876 (95%) 1,026 (94%) 850 (95%) 418 (96%) 608 (93%) 605 (94%) 245 (97%)
Passive thoughts 56 (3%) 35 (3%) 21 (2%) 9 (2%) 26 (4%) 18 (3%) 3 (1%)
Active thoughts 46 (2%) 27 (2%) 19 (2%) 7 (2%) 20 (3%) 18 (3%) 1 (0%)
Not assessed 6 (0%) 3 (0%) 3 (0%) 1 (0%) 2 (0%) 0 (0%) 3 (1%)
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Clinician counseling 206 (56%) 191 (89%) 15 (10%) 77 (89%) 114 (90%) 11 (9%) 4 (10%)
FB counseling 134 (36%) 0 (0%) 134 (86%) 0 (0%) 0 (0%) 103 (88%) 31 (79%)
AD 1 (0%) 1 (0%) 0 (0%) 0 (0%) 1 (1%) 0 (0%) 0 (0%)
AD & clinician 
counseling 1 (0%) 1 (0%) 0 (0%) 0 (0%) 1 (1%) 0 (0%) 0 (0%)
AD & FB counseling 2 (1%) 0 (0%) 2 (1%) 0 (0%) 0 (0%) 2 (2%) 0 (0%)




Clinician counseling 62 (47%) 60 (79%) 2 (4%) 18 (62%) 42 (89%) 1 (2%) 1 (8%)
FB counseling 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
AD 48 (37%) 7 (9%) 41 (75%) 5 (17%) 2 (4%) 37 (86%) 4 (33%)
AD & clinician 
counseling 15 (11%) 7 (9%) 8 (15%) 5 (17%) 2 (4%) 3 (7%) 5 (42%)
AD & FB counseling 4 (3%) 0 (0%) 4 (7%) 0 (0%) 0 (0%) 2 (5%) 2 (17%)
None 2 (2%) 2 (3%) 0 (0%) 1 (3%) 1 (2%) 0 (0%) 0 (0%)
*Those with missing baseline treatment plan (n=4) treated as none; AD=antidepressants, FB=Friendship Bench 
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Provision of depression treatment over first 6 months on ART during active phase
Window (Day since ART initiation)
0 1–45 46–76 77–106 107–137 138–167 168–197
Of those directed to FB:
HIV appointment attended & 
FB session attended 130 (93%) 62 (44%) 50 (36%) 46 (33%) 31 (22%) 9 (6%) 11 (8%)
HIV appointment attended; 
completed 6 FB sessions 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 10 (7%) 12 (9%)
HIV appointment attended 
but no FB session 10 (7%) 40 (29%) 44 (31%) 38 (27%) 36 (26%) 36 (26%) 29 (21%)
Did not come to clinic 0 (0%) 37 (26%) 43 (31%) 49 (35%) 60 (43%) 69 (49%) 70 (50%)
Transferred out 0 (0%) 1 (1%) 3 (2%) 7 (5%) 13 (9%) 16 (11%) 18 (13%)
Of those prescribed 
antidepressants:*
PHQ-9 assessed; AD 
provided 55 (100%) 20 (36%) 10 (18%) 12 (22%) 13 (24%) 8 (15%) 4 (7%)
PHQ-9 assessed; no AD 
provided 0 (0%) 5 (9%) 8 (15%) 6 (11%) 3 (5%) 1 (2%) 1 (2%)
No PHQ-9 assessed; no AD 
provided 0 (0%) 18 (33%) 15 (27%) 15 (27%) 11 (20%) 13 (24%) 17 (31%)
Did not come to clinic 0 (0%) 11 (20%) 20 (36%) 20 (36%) 25 (45%) 29 (53%) 29 (53%)
Transferred out 0 (0%) 1 (2%) 2 (4%) 2 (4%) 3 (5%) 4 (7%) 4 (7%)
*antidepressants include either AD and AD and FB; AD = antidepressants; FB = Friendship Bench
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Of those who were directed to receive Friendship Bench counseling, 93 percent started 
Friendship Bench counseling the same day they initiated ART (Figure 5). During the first follow-
up visit window (between days 1 and 45), only 44 percent of these patients also attended a 
Friendship Bench session. By the 6-month window (between days 168 and 197), only 8 percent 
of these patients also attend a Friendship Bench session and only 9 percent attended an ART 
appointment and had attended six Friendship Bench sessions prior to the start of this window. 
Over the course of the first six months of care, an increasing proportion of patients did not come 
to the clinic; by the 6-month window half of patients did not attend an appointment. 
Figure 5  Provision of depression treatment over first 6 months on ART during the active phase 
                among those directed to receive Friendship Bench counseling (N=140)
FB=Friendship Bench
Of the patients prescribed antidepressants, one-third received a second prescription of 
antidepressants at their first follow-up visit. By the 6-month window (between days 168 and 
197), only 7 percent of patients attended an appointment and received antidepressants (Figure 
6). During every follow-up window, between 20 percent and 33 percent of patients attended an 
appointment, but were not reassessed with the PHQ-9 and thus did not receive antidepressants. 
Similar to the patients who were referred for Friendship Bench counseling, patients who started 
antidepressants increasingly did not come to the clinic; by the 6-month window over half of 







Did not come to clinic
Transferred out
Died
HIV appointment attended & FB session attended
HIV appointment attended; completed 6 FB sessions
HIV appointment attended but no FB session
1–45 46–76 77–106 107–137 138–167 168–197
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Figure 6  Provision of depression treatment over first 6 months on ART during the active phase 








Did not come to clinic
Transferred out
Died
PHQ-9 assessed; AD provided
PHQ-9 assessed; no AD provided
No PHQ-9 assessed; no AD provided
1–45 46–76 77–106 107–137 138–167 168–197
Integrating depression management into HIV care in Lilongwe, Malawi: FeasIbility and impact   ■  35
Project SOAR
Population Council
4301 Connecticut Ave, NW, 
Suite 280
Washington, D.C. 20008 USA
Tel: +1 202 237 9400
Fax: +1 202 237 8410 
projsoar.org
